In brief: Biodiem; Avexa
Tuesday, 11 January, 2005
BioDiem (ASX:BDM) has received a US$1m signing-on payment, the first in a number of milestone payments due under its US$8m licence agreement with Akzo Nobel's Nobilon.
Avexa antibacterial studies confirmed
Maryland-based company ImQuest BioSciences has confirmed the activity of Avexa's (ASX: AVX) antibacterial compounds against vancomycin-resistant enterococci (VRE).
Avexa aims to have a lead compound in proof-of-concept models by the end of 2005.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
